Ipilimumab API is a pharmaceutical-grade fully human monoclonal antibody that targets Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4), an immune checkpoint receptor that negatively regulates T-cell activation. By blocking CTLA-4, Ipilimumab enhances the body's immune response against cancer cells, improving antitumor activity.
Ipilimumab is approved for the treatment of unresectable or metastatic melanoma and is also used in combination with other immune checkpoint inhibitors for the treatment of renal cell carcinoma, hepatocellular carcinoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, microsatellite instability-high (MSI-H) colorectal cancer, and other advanced malignancies.
Manufactured under WHO-GMP-certified biopharmaceutical facilities, our Ipilimumab API is produced using advanced recombinant biotechnology processes to ensure exceptional purity, biological activity, stability, and batch-to-batch consistency. Every batch undergoes comprehensive quality testing and is supplied with Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and complete regulatory documentation.
Ipilimumab API is used in injectable immunotherapy formulations for the treatment of melanoma and several advanced cancers through immune checkpoint inhibition.
Ipilimumab blocks the CTLA-4 receptor on T cells, enhancing immune activation and enabling the immune system to recognize and destroy cancer cells more effectively.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Ipilimumab API in commercial quantities for pharmaceutical and biopharmaceutical manufacturing worldwide.
Get Bulk Quote via WhatsApp